Iselin NJ, April 21, 2009 – Pharmos Corporation (OTCBB – PARS.PK) announced today that it has completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is […]
Iselin NJ, April 2, 2009 – Pharmos Corporation (OTCBB – PARS.PK) issued the following business update on the Dextofisopam Phase 2b trial and the status of financing operations. Dextofisopam Phase 2b trial As previously announced on March 4, 2009, Pharmos modified the size of the Dextofisopam Phase 2b trial for Irritable Bowel Syndrome IBS D+A to a minimum 300 patient trial. The trial is now essentially […]
Iselin NJ, March 6, 2009 – Pharmos Corporation (Nasdaq: PARS) announced today that it has received a Nasdaq Staff Determination that the company is not in compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing. Unless the company appeals the determination, its securities will be removed from listing and registration on The Nasdaq Stock Market. Pharmos does not intend to appeal the determination. The […]
Iselin NJ, March 4, 2009 – Pharmos Corporation (Nasdaq: PARS) announced today that it has completed a reevaluation of the size of the Phase 2b Dextofisopam trial for Irritable Bowel Syndrome IBS -D + A and has concluded that a smaller trial could achieve the objectives of the trial. As the Phase 2b trial is not going to be a registration /pivotal trial, the objectives that […]
Iselin NJ, February 27, 2009 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2008. Fourth Quarter Ended December 31, 2008 The Company recorded a net loss of $1.0 million, or $0.04 per share, for the fourth quarter 2008 compared to a net loss of $2.7 million, or $0.11 per share, in the fourth quarter 2007. […]
Iselin NJ, February 18, 2009 – Pharmos Corporation (Nasdaq: PARS) announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the patent rights and technical know how related to the compound known as PRS-639,058 and some follow on molecules. These CB2-selective cannabinoids are synthetic compounds which belong to the class of nonclassical cannabinoids and […]
Iselin NJ, November 19, 2008 – Pharmos Corporation (Nasdaq: PARS) today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-blinded, placebo-controlled study evaluated the safety and efficacy of the Company’s 3% Diclofenac Diethanolamine NanoEmulsion cream in 104 patients with chronic pain due to osteoarthritis of the knee. Patients applied the […]
Iselin NJ, November 13, 2008 – Pharmos Corporation (Nasdaq: PARS) today announced that it received notice from The Nasdaq Stock Market (“Nasdaq”) on November 11, 2008 that the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(3), which requires the Company to have a minimum of $2,500,000 in stockholders’ equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations […]
Iselin NJ, November 6, 2008 – Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2008. The Company recorded a net loss of $2.8 million, or $0.1 1 per share, for the third quarter 2008 compared to a net loss of $3.5 million, or $0.14 per share, in the third quarter 2007. Cash and cash equivalents totaled $6.1 million at September […]
Iselin NJ, September 26, 2008 – Pharmos Corporation (Nasdaq: PARS) today announced that it received a Nasdaq Staff Determination on September 23, 2008 indicating that Pharmos fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4), and that the Staff has therefore determined to delist Pharmos’ securities from The Nasdaq Capital Market. Pharmos has requested a hearing before […]